- What: Using NextBio to Unlock the Knowledge in Public and Proprietary Experimental and Clinical Data
- When: May 28th, 2014: 10 am
- Where:Magee-Womens Research Institute (MWRI), 1st floor conference room
- Who:Dr. James Flynn, Sr. Field Application Scientist-Enterprise Informatics, Illumina, Inc.
Traditional drug development paradigms are shifting toward gaining proof of concept information on clinical benefit as early as possible in distinct patient populations based on biomarker profiles. NextBio’s Translational Medicine ecosystem is a web-based discovery and integration platform that provides a practical way to mine vast quantities of complex biological and clinical data. NextBio engineered new paradigms of correlative, data-driven discovery that is proving to accelerate biomedical research by combining semantically structured data from private and public cross-platform ‘omics’ data. Advances in summarizing patient level attributes, therapies, molecular profiles, survival and drug sensitivity reporting enrich clinical development programs with deep-reaching prognostic and therapeutic guidance for individual patients and distinct populations.